English and Chinese Sessions to be Held to Accommodate Multiple Time Zones
FOSTER CITY, Calif., SHANGHAI and HANGZHOU, China, Jan. 12, 2022 (GLOBE NEWSWIRE) — Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the management team will host two upcoming webcasts to accommodate participants from the U.S. and China. Co-Founder, Chairman and Chief Executive Officer, Guo-Liang Yu, PhD, will be joined by Sanjeev Redkar, PhD, Co-Founder and President, K. Peony Yu, M.D., Chief Medical Officer, and Wilson W. Cheung, CPA, Chief Financial Officer, to provide a strategic overview and an update on the Company’s pipeline programs.
Session Dates/Times:
Session | U.S. Pacific | U.S. Eastern | China | Europe |
English | January 26th 11:00 a.m. |
January 26th 2:00 p.m. |
January 27th 3:00 a.m. |
January 26th 8:00 p.m. |
Chinese | January 26th 7:00 p.m. |
January 26th 10:00 p.m. |
January 27th 11:00 a.m. |
January 27th 4:00 a.m. |
All are invited to listen to the event and view the presentation via webcast on the Apollomics website under the News/Events section: Events and Presentations. An archive of the webcast will be available for three months.
About Apollomics Inc.
Apollomics Inc. is an innovative biopharmaceutical company committed to the discovery and development of monotherapies and combination therapies of tumor-targeting and immuno-oncology agents. The Company’s product pipeline has several programs at different stages of development, including novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Apollomics has operating entities in Foster City, California, USA, Hangzhou and Shanghai, China. For more information, please visit www.apollomicsinc.com.
Contact Information:
Investor Contact:
Wilson W. Cheung
Chief Financial Officer
(650) 209-4436
wcheung@apollomicsinc.com
U.S. Media Contact:
Remy Bernarda
Corporate Communications
(415) 203-6386
remy.bernarda@apollomicsinc.com
China Media Contact:
Porda Havas International Finance Communications Group
Kelly Fung
General Manager
(852) 3150 6763
kelly.fung@pordahavas.com
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere…
Bicameral legislation seeks to codify annual examinations and assessments for assistive technologies, including Personal Exoskeletons,…
New studies at Mount Sinai Health System and Penn Medicine investigate how the brain controls…
PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT A LEADING EUROPEAN BREAST CANCER CONFERENCEANGLE presenting two…
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 22, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today…